Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06360354 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)
A Phase 1 study of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT06360354: Recruiting Phase 1 study of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, sponsored by Amgen.
NCT06360354 is a Phase 1 study of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers that is actively recruiting participants, run by Amgen. The registered enrollment target is 350 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (483% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06360354, a Phase 1 study of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG RMC-6236
- DRUG AMG 193
- DRUG Modified FOLFIRINOX
Study Locations (20)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- City of Hope National Medical Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Duarte
- University of California San Diego Moores Cancer Center - La Jolla
- Translational Research in Oncology US Inc, Trio Central Pharmacy - Los Angeles
- University of California Los Angeles - Santa Monica
Connecticut
- Hartford Hospital - Hartford
- Yale University - New Haven
- Norwalk Hospital - Norwalk
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Colorado
- Rocky Mountain Cancer Centers - Aurora
Illinois
- University of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Kentucky
- Norton Cancer Institute - Louisville
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2024-05-29 |
| Est. Completion | 2029-02-25 |
| Phase | Phase 1 |
What NCT06360354 shows while recruiting
NCT06360354 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (483% higher).
The record links to 1 condition, with Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT06360354 names 20 study sites across 12 states, led by California, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06360354 about?
NCT06360354 is a clinical study titled "A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)". The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastroin...
What is the current status of trial NCT06360354?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 350 participants. The study started on 2024-05-29. Estimated completion is 2029-02-25.
What conditions does trial NCT06360354 study?
This clinical trial studies the following conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers.
What interventions are being tested in trial NCT06360354?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), RMC-6236 (DRUG), AMG 193 (DRUG), Modified FOLFIRINOX (DRUG).
Who is sponsoring clinical trial NCT06360354?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06360354 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06360354's enrollment target sits among peer trials
350 97th of 2000 higher than 1,903 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI